Demographics, treatment regimens and the use of angiotensin-receptor blockers in heart failure: Findings from the Valsartan Heart Failure Trial

Journal of International Medical Research

Volumn 31, Issue 5, 2003, Pages 351-361

  Majahalme, Silja ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Aetiology; Angiotensin receptor blockers; Co morbidities; Diabetes; Gender; Heart failure; Renin angiotensin system; Risk factors; Treatment response

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; VALSARTAN; WARFARIN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; DEMOGRAPHY; DEVELOPED COUNTRY; DRUG EFFICACY; EARLY DIAGNOSIS; ETHNIC GROUP; GROUPS BY AGE; HEART FAILURE; HUMAN; INCIDENCE; PREVALENCE; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE;

EID: 0142211396     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000303100501     Document Type: Review

References (71)

1. McMurray J, McDonagh T, Morrison CE, Dargie HJ: Trends in hospitalization for heart failure in Scotland 1980 - 1990. Eur Heart J 1993; 14: 1158-1162.
2. Cleland JGF, Gemmell I, Khand A, Boddy A: Is the prognosis of heart failure improving? Eur J Heart Fail 1999; 1: 229-241.
3. Bonneux L, Barendregt JJ, Meeter K, Bonsel GJ, van der Maas PJ: Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure. Am J Public Health 1994; 84: 20-28.
4. Mair FS, Crowley TS, Bundred PE. Prevalence, aetiology and management of heart failure in general practice. Br J Gen Pract 1996; 46: 77-79.
5. Remme WJ, Swedberg K, for the Task Force for the Diagnosis and Treatment of Chronic Heart Failure: Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-1560.
6. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, et al: Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349-1353.
7. ACC/AHA Task Force: ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult. American College of Cardiology and the American Heart Association, Inc., 2001.
8. The CIBIS-II Investigators: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
9. The MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
10. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
11. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
12. Cohn JN, Tognoni G, the Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
13. Wilson PW: From hypertension to heart failure: what have we learned? Clin Cardiol 1999; 22 (Suppl 5): V1-V10.
14. Benetos A, Thomas F, Safar ME, Bean KE, Guize L: Should diastolic and systolic blood pressure be considered for cardiovascular risk evaluation: a study in middle-aged men and women. J Am Coll Cardiol 2001; 37: 163-168.
15. Kannel WB: Nutrition and the occurrence and prevention of cardiovascular disease in the elderly. Nutr Rev 1988; 46: 68-78.
16. Johnson CL, Rifkind BM, Sempos CT, Carroll MD, Bachorik PS, Briefel RR, et al: Declining serum total cholesterol levels among US adults. The National Health and Nutrition Examination Surveys. JAMA 1993; 269: 3002-3008.
17. Mejhert M, Holmgren J, Wandell P, Persson H, Edner M: Diagnostic tests, treatment and follow-up in heart failure patients - is there a gender bias in the coherence to guidelines? Eur J Heart Fail 1999; 1: 407-410.
18. Harjai KJ, Nunez E, Stewart Humphrey J, Turgut T, Shah M, Newman J: Does gender bias exist in the medical management of heart failure? Int J Cardiol 2000; 75: 65-69.
19. Kitzman DW, Gardin JM, Gottdiener JS, Arnold A, Boineau R, Aurigemma G, et al: Importance of heart failure with preserved systolic function in patients ≥ 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol 2001; 87: 413-419.
20. Adams KF, Jr, Dunlap SH, Sueta CA, Clarke SW, Patterson JH, Blauwet MB, et al: Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol 1996; 28: 1781-1788.
21. Lindenfeld J, Krause-Steinrauf H, Salerno J: Where are all the women with heart failure? J Am Coll Cardiol 1997; 30: 1417-1419.
22. Cleland JGF, Swedberg K, Cohen-Solal A, Cosin-Aguilar J, Dietz R, Follath F, et al: Increasing awareness and improving the management of heart failure in Europe: the IMPROVEMENT of HF initiative. The Study Group on Diagnosis of the Working Group on Heart Failure of The European Society of Cardiology. Eur J Heart Fail 1999; 1: 139-144.
23. Goodwin L: The aging heart - implications for underwriting. Transamerica Reinsurance Risk Newsletter October 1999; available at http://www.transamericareinsurance.com/news_articles_the_aging_heart.asp (last accessed 1 May 2003).
24. Davis RC, Hobbs FD, Lip GY: ABC of heart failure. History and epidemiology. BMJ 2000; 320: 39-42.
25. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, et al: Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 2000; 35: 1628-1637.
26. Muntwyler J, Follath F: [Medical treatment of heart failure: an analysis of actual treatment practices in outpatients in Switzerland. The Swiss "IMPROVEMENT of HF" Group]. Schweiz Med Wochenschr 2000; 130: 1192-1198.
27. Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L: Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997; 277: 115-121.
28. Viskin S, Kitzis I, Lev E, Zak Z, Heller K, Villa Y, et al: Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. J Am Coll Cardiol 1995; 25: 1327-1332.
29. Gottlieb SS, McCarter RJ, Vogel RA: Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489-497.
30. Flamenbaum W: Diuretic use in the elderly: potential for diuretic-induced hypokalemia. Am J Cardiol 1986; 57: 38A-43A.
31. Ho KK, Pinsky JL, Kannel WB, Levy D: The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22 (4 Suppl A): 6A-13A.
32. Pollare T, Lithell H, Selinus I, Berne C: Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989; 298: 1152-1157.
33. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-1355.
34. Jacob S, Rett K, Henriksen EJ: Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998; 11: 1258-1265.
35. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, et al: Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997; 126: 955-959.
36. Dahlöf B, Devereux R, Kjeldsen S, Julius S, Beevers G, de Faire U, et al: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
37. Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz; A, Werhlen-Grandjean M, et al: Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001; 103: 1428-1433.
38. Joglar JA, Acusta AP, Shusterman NH, Ramaswamy K, Kowal RC, Barbera SJ, et al: Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 2001; 142: 498-501.
39. Cleland JG, Thygesen K, Uretsky BF, Armstrong P, Horowitz JD, Massie B, et al: Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. Eur Heart J 2001; 22: 1601-1612.
40. Khand AU, Gemmell I, Rankin AC, Cleland JG: Clinical events leading to the progression of heart failure: insights from a national database of hospital discharges. Eur Heart J 2001; 22: 153-164.
41. Baker DW, Jones R, Hodges J, Massie BM, Konstam MA, Rose EA: Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. JAMA 1994; 272: 1528-1534.
42. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996; 335: 1107-1114.
43. Massie BM, Fisher SG, Deedwania PC, Singh BN, Fletcher RD, Singh SN: Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. Circulation 1996; 93: 2128-2134.
44. Krumholz HM, Chen YT, Radford MJ: Aspirin and the treatment of heart failure in the elderly. Arch Intern Med 2001; 161: 577-582.
45. Cleland JG, John J, Dhawan J, Clark A: What is the optimal medical management of ischaemic heart failure? Br Med Bull 2001; 59: 135-158.
46. Dauterman KW, Go AS, Rowell R, Gebretsadik T, Gettner S, Massie BM: Congestive heart failure with preserved systolic function in a statewide sample of community hospitals. J Card Fail 2001; 7: 221-228.
47. Philbin EF, Rocco TA, Jr: In Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function. Am Heart J 1997; 134: 188-195.
48. Vasan RS, Benjamin EJ, Levy D: Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995; 26: 1565-1574.
49. Gheorghiade M, Bonow RO: Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 1998; 97: 282-289.
50. Bourassa MG, Gurne O, Bangdiwala SI, Ghali JK, Young JB, Rousseau M, et al: Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. J Am Coll Cardiol 1993; 22: 14A-19A.
51. American Heart Association. High Blood Pressure Statistics. Dallas, TX, USA: American Heart Association, 1999.
52. El-Gharbawy AH, Kotchen JM, Grim CE, Kaldunski M, Hoffmann RG, Pausova Z, et al: Predictors of target organ damage in hypertensive blacks and whites. Hypertension 2001; 38: 761-766.
53. Dunlap SH, Sueta CA, Tomasko L, Adams KF, Jr: In Association of body mass, gender and race with heart failure primarily due to hypertension. J Am Coll Cardiol 1999; 34: 1602-1608.
54. The Beta-blocker Evaluation of Survival Trial Investigators: A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344: 1659-1667.
55. Lowes BD, Gilbert EM, Lindenfeld JA, Zelis R, Domanski MJ, Eichhorn EJ, et al: Differential effects of β-blocking agents on adrenergic activity. Circulation 2000; 102 (Suppl II): 628-629.
56. Eichhorn EJ, Domanski MJ, Adams K, Anderson JL, Bristow MR, Carson P, et al: Effect of β-blockade on mortality in African-Americans: The β-Blocker Evaluation of survival trial. Circulation 2000; 102 (Suppl II): 778.
57. Plehn JF, Krause-Steinrauf H, Anand IS, Gottlieb S, O'Connor CM, Silver MA, et al: Effect of race on cause-specific cardiovascular mortality in best. Circulation 2000; 102 (Suppl II): 79.
58. Hall WD: Representation of blacks, women, and the very elderly (aged ≥ 80) in 28 major randomized clinical trials. Ethn Dis 1999; 9: 333-340.
59. Cohn JN, Tognoni G, Glazer RD, Spormann D, Hester A: Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail 1999; 5: 155-160.
60. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T: International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-472.
61. Urata H, Nishimura H, Ganten D: Chymase-dependent angiotensin II forming systems in humans. Am J Hypertens 1996; 9: 277-284.
62. Wolny A, Clozel JP, Rein J, Mory P, Vogt P, Turino M, et al: Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 1997; 80: 219-227.
63. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ: A human homolog of angiotensin converting enzyme - cloning and functional expression as a captopril insensitive carboxypeptidase. J Biol Chem 2000; 275: 33238-33243.
64. Israili ZH, Hall WD: Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor, therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234-242.
65. de Gasparo M, Siragy HM: The AT2 receptor: fact, fancy and fantasy. Regul Pept 1999; 81: 11-24.
66. Tamura T, Said S, Harris J, Lu W, Gerdes AM: Reverse remodeling of cardiac myocyte hypertrophy in hypertension and failure by targeting of the renin-angiotensin system. Circulation 2000; 102: 253-959.
67. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-752.
68. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587.
69. Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G, et al: Candesartan in heart failure - assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. J Card Fail 1999; 5: 276-282.
70. Maggioni A, Anand I, Gottlieb S, Latini R, Tognoni G, Cohn J: Effects of valsartan on morbidity and mortality in patients with heart failure not receiving ACE-inhibitors. J Am Coll Cardiol 2002; 40: 1414-1421.
71. Maggioni A, Carson P, Soler J, Chiang Y-T, Aknay N, Cohn J: Valsartan shows consistent efficacy across heart failure patient subgroups: results from Val-HeFT. Eur Heart J 2002; 23 (Suppl 4): 327.